Today: 20 June 2026

Nasdaq Warning and EV Ambitions: Carbon Revolution (CREV) Races to Reinvent Itself

Nasdaq Warning and EV Ambitions: Carbon Revolution (CREV) Races to Reinvent Itself

Carbon Revolution faces possible Nasdaq delisting after failing equity and filing requirements, with deadlines set for late 2025. CREV shares traded at $3.73 on Oct. 17, 2025, down over 70% from their 52-week high, valuing the company under $7 million. Fiscal 2024 revenue hit a record $47.3 million, but net loss reached $146.4 million. The company warned it needs more funding within a quarter to remain solvent.
17 October 2025
··
Credit ‘Cockroach’ Jitters Shake Markets: Stocks Slide Globally as Gold Hits Record High

Credit ‘Cockroach’ Jitters Shake Markets: Stocks Slide Globally as Gold Hits Record High

Global stocks tumbled Thursday as fresh U.S. regional bank troubles triggered a worldwide selloff. The Dow fell 410 points, while Zions Bancorp and Western Alliance shares dropped 10% after disclosing bad loans and alleged fraud. Gold hit a record $4,378/oz as investors rushed to safe havens. Europe’s bank index slid 2.7%, and major Asian markets closed sharply lower.
17 October 2025
·······
Fraud Scandals Spark Market Selloff as ‘Cockroach’ Credit Fears Mount

Fraud Scandals Spark Market Selloff as ‘Cockroach’ Credit Fears Mount

Over $100 billion in U.S. bank market value was erased Thursday as the Dow fell nearly 400 points and the KBW Regional Banking Index dropped 6%. Zions Bancorp and Western Alliance plunged after disclosing fraud-related loan losses, sparking broad financial sector selloffs. Gold hit a record above $4,370/oz and Treasury yields slid as investors fled to safe havens. Wall Street leaders warned of wider credit risks.
17 October 2025
···
Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

Artiva Biotherapeutics (ARTV) Stock Skyrockets on FDA Fast Track News – What’s Next for Investors?

Artiva Biotherapeutics shares surged nearly 100% in after-hours trading Oct. 16 after the FDA granted Fast Track status to its AlloNK cell therapy for refractory rheumatoid arthritis. The stock jumped from a $2.77 close to as high as $6.33. Over 20 patients have received AlloNK in trials, with key safety and mechanistic data expected by mid-November. Artiva plans to begin a pivotal Phase 3 trial in 2026, pending results.
17 October 2025
·
Truist’s Q3 Earnings Beat and 5% Dividend Yield Trigger Rally as Analysts Grow Bullish

Truist’s Q3 Earnings Beat and 5% Dividend Yield Trigger Rally as Analysts Grow Bullish

Truist Financial reported Q3 earnings of $1.04 per share, beating estimates, with net income rising to $1.35 billion on $5.24 billion revenue. Shares jumped 4% after results but remain down 5.3% year-to-date. Fee income surged 11% sequentially, offsetting flat net interest income. The bank maintained its $0.52 dividend and repurchased $500 million in stock.
17 October 2025
···
Reliance Q2 Results Boost Investor Hopes – Double-Digit Growth, Jio IPO Buzz & Stock Breakout?

Reliance Q2 Results Boost Investor Hopes – Double-Digit Growth, Jio IPO Buzz & Stock Breakout?

Reliance Industries is expected to report Q2 FY26 net profit of ₹18,000–21,000 crore, up about 10% year-on-year, with revenue rising to ₹2.52–2.57 lakh crore. The gains are driven by strong oil-to-chemicals margins and growth in Jio and retail. The stock has rebounded 4% in October after a post-Q1 drop. Investors await updates on a potential Jio IPO and progress in new energy and AI initiatives.
17 October 2025
····
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Surges on Obesity Drug Boom and Alzheimer’s Breakthroughs – Is $1,000 Next?

Eli Lilly shares hit a record $832 intraday on Oct. 1, fueled by demand for its obesity drugs and Alzheimer’s advances, before slipping 4% after Donald Trump pledged to cut weight-loss drug prices. Lilly’s Mounjaro and ZepBound now hold 57% of U.S. GLP-1 prescriptions, outpacing Novo Nordisk. First-half 2025 revenue jumped about 40% year-on-year. Most analysts remain bullish, despite valuation and policy concerns.
17 October 2025
··
Bank of America (BAC) Stock Soars on Earnings Beat – Can It Keep Climbing?

Bank of America (BAC) Stock Soars on Earnings Beat – Can It Keep Climbing?

Bank of America shares traded near $50 midday Friday, down about 1.5% after a 3.5% drop Thursday erased post-earnings gains. The bank reported Q3 net income of $8.5 billion and revenue of $28.1 billion, both above estimates. BAC raised its Q4 net interest income outlook and boosted its dividend. Analyst price targets rose after earnings, with the average 12-month target at $56.
17 October 2025
··
Palantir’s Shocking Reinvention: From Secretive Spy Tech to $400B Cult Lifestyle Brand

Palantir (PLTR) Stock Soars 300% on AI Mega-Deals – Boom or Bubble Ahead?

Palantir shares traded near $178–$180 on October 17, 2025, up 300% year-to-date and just below August’s record high. The surge follows major AI contracts, including a $10 billion U.S. Army deal and a new partnership with Snowflake. Q2 revenue rose 48% to $1.03 billion, with profit at $327 million. At $180 per share, Palantir’s valuation exceeds $425 billion, drawing both bullish targets and warnings of a bubble.
17 October 2025
···
Solana’s $195 Lifeline: Can Bulls Turn This Dip Into a $250+ Comeback Rally?

Solana’s $195 Lifeline: Can Bulls Turn This Dip Into a $250+ Comeback Rally?

Solana’s price has dropped to around $186–$195 after peaking above $250 in early October, testing a key support zone. Nearly $400 million in SOL left exchanges in recent days, signaling heavy profit-taking and reduced liquidity. Andreessen Horowitz invested $50 million in a Solana staking firm, while Forward Industries raised $1.65 billion to buy SOL. Analysts see $186–$195 as critical; failure to hold could send SOL toward $172 or lower.
17 October 2025
·
SoFi’s Roller-Coaster Rally: Fintech Stock Soars 230% in 2025 – What’s Next for SOFI?

SoFi’s Roller-Coaster Rally: Fintech Stock Soars 230% in 2025 – What’s Next for SOFI?

SoFi shares surged 230% over the past year, hitting a 52-week high of $30.30 in late September before dropping to $26.60 on Oct. 16. The company will report Q3 earnings on Oct. 28, with analysts expecting EPS of $0.08 on $880 million in revenue. SoFi recently launched fee-free options trading and an AI-focused ETF, and plans to enable crypto payments by late 2025. CEO changes and student loan policy developments are also in focus.
17 October 2025
··
INVO Fertility (IVF) Stock’s Wild 90% Surge Amid IVF Boom – What’s Behind the Frenzy?

INVO Fertility (IVF) Stock’s Wild 90% Surge Amid IVF Boom – What’s Behind the Frenzy?

INVO Fertility shares jumped nearly 90% to $1.43 on Oct. 16, 2025, with volume topping 108 million amid a sector rally sparked by White House plans to expand IVF access. The stock briefly surpassed $2 before dropping about 30% early the next day as traders took profits. INVO raised $200,000 in a preferred share sale and filed to register 8.35 million shares for resale. The company remains unprofitable and cash-strapped.
17 October 2025
·
Amazon Stock Today: AI Ambitions, $2.5B Twist, and $3 Trillion Dreams

Amazon Stock Rebound Stalls: AI Ambitions, $2.5B Settlement & the $3 Trillion Question

Amazon shares traded near $214 on Oct. 17 after falling almost 5% from $228 last week during a tech sector sell-off. Year-to-date, the stock is up about 3%, trailing the Nasdaq’s 15% gain. The company recently settled an FTC probe for $2.5 billion and announced new AI initiatives, but remains roughly 10% below its February 2025 high.
17 October 2025
····
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

Novo Nordisk shares fell 6.7% in Copenhagen on Oct. 17, 2025, and U.S. pre-market quotes pointed to a further 4.8% drop. The stock has lost over 40% year-to-date, erasing hundreds of billions in value. Recent acquisitions and job cuts have not reversed investor caution, as competition from Eli Lilly intensifies and analysts warn of more profit downgrades.
17 October 2025
··
Oracle’s ‘Truly Awesome’ AI Cloud Quarter Sends Stock Soaring 36%, Making Ellison World’s Richest

Oracle’s $300B AI Cloud Bet Sends Stock Soaring – Trillion-Dollar Dreams Awaken

Oracle shares surged over 36% on September 10, 2025, after announcing $300 billion in new AI cloud contracts, including a major deal with OpenAI. The stock hit an all-time high near $345, then pulled back on margin concerns but remains up about 70–80% year-to-date. Fiscal Q1 revenue rose 12% to $14.93 billion, driven by 28% cloud growth. Oracle’s backlog soared to $455 billion, up 359% from a year earlier.
17 October 2025
···
Apple’s July 2025 Bombshells: Foldable iPhone, AI Secrets, Encryption Showdown & More

Apple Stock Surges on New Products and iPhone 17 “Supercycle” – Analysts Split on AAPL’s Next Move

Apple shares hovered near $247–$249 this week, just below their record high. On Oct. 15, Apple launched new M5 chip devices, including a refreshed MacBook Pro and Vision Pro headset, without raising prices. Early iPhone 17 sales are running 10–15% above last year’s launch. CEO Tim Cook remains, but succession plans are in motion, with John Ternus seen as a likely successor.
17 October 2025
··
1 … 1,893 1,894 1,895 1,896 1,897 … 2,088

Stock Market Today

  • TD Cowen Confirms Hold Rating on Banco Bradesco S.A. Despite Undervaluation
    June 20, 2026, 3:53 PM EDT. TD Cowen maintained a Hold rating on Banco Bradesco S.A. (NYSE:BBD) following its fiscal Q1 2026 earnings release. The Brazilian bank reported R$36.9 billion in revenue, below estimates, causing a 6.4% stock decline. However, its loan portfolio grew 8.4% year-over-year to R$1.09 trillion, driven by secured lending. Banco Bradesco trades at a forward price-to-earnings (P/E) ratio of 6.7, below the sector average of 11, suggesting undervaluation. Analysts forecast over 31% upside in the next 12 months. Management maintains its 2026 guidance with expected loan growth of 9.5% and risk-adjusted net interest income growth of 12.5%. Investors are advised to weigh this against higher-upside, lower-risk AI stock opportunities amid broader market trends.

Latest articles

Robinhood Gains for Week as Layoffs, Trading Volumes Boost Shares

Robinhood Gains for Week as Layoffs, Trading Volumes Boost Shares

20 June 2026
Robinhood soared 16% in a holiday-shortened week after announcing a 10% workforce cut and $28 million in restructuring charges, as investors viewed the move as cost control amid record June trading volumes; risks remain from competition and potential disruption, according to SEC filings and Reuters.
Go toTop